Premium
Immunohistochemical analysis of cyclooxygenase‐2 and brain fatty acid binding protein expression in grades I ‐ II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy
Author(s) -
Kang HyunCheol,
Kim Il Han,
Park Charn Il,
Park SungHye
Publication year - 2014
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/neup.12128
Subject(s) - immunohistochemistry , cyclooxygenase , medicine , radiation therapy , proportional hazards model , biomarker , confounding , pathology , meningioma , brain tumor , oncology , enzyme , biology , biochemistry
This study was done to evaluate the association of cyclooxygenase 2 ( COX ‐2) and brain fatty acid binding protein ( BFABP ) with tumor grade and outcome of grades I ‐ II meningiomas treated with radiotherapy. From 1996 to 2008, 40 patients with intracranial grades I ‐ II meningiomas were treated with radiotherapy. Immunohistochemical staining for COX ‐2 and BFABP were performed on formalin‐fixed paraffin‐embedded tissues. COX ‐2 expression was significantly associated with BFABP status and both COX ‐2 ( P < 0.01) and BFABP ( P = 0.01) expression were stronger in the grade II meningiomas than in grade I tumors. Among the clinicopathologic factors, age and COX ‐2 status were prognostic in progression‐free survival. Patients with moderate or strong COX ‐2 expression had worse outcome than those with negative or weak COX ‐2 expression ( P = 0.03) after controlling for potential confounders. Our results suggest that the molecular biomarker COX ‐2 has prognostic significance in intracranial grades I ‐ II meningiomas following radiotherapy.